Insider purchase: Processa (NASDAQ: PCSA) CAO adds 2,436 shares in open-market buy

Rhea-AI Filing Summary

Processa Pharmaceuticals insider activity: Chief Administrative Officer Guy Wendy bought 2,436 shares of common stock in an open-market purchase at $1.93 per share. After this trade, she holds 14,394 shares directly and 333 shares indirectly through CorLyst, LLC.

Insider Trade Summary

Net Buyer: 2,436 shares ($4,701)

Net Buy 2 txns

Insider Guy Wendy

Role Chief Administrative Officer

Bought 2,436 shs ($5K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	2,436	$1.93	$5K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 14,394 shares (Direct, null); Common Stock — 333 shares (Indirect, By CorLyst, LLC)

Footnotes (1)

Key Figures

Shares purchased: 2,436 shares Purchase price: $1.93 per share Direct holdings after: 14,394 shares +2 more

5 metrics

Shares purchased 2,436 shares Open-market purchase of common stock

Purchase price $1.93 per share Price for the 2,436 common shares bought

Direct holdings after 14,394 shares Common stock directly owned after the transaction

Indirect holdings after 333 shares Common stock indirectly owned through CorLyst, LLC

Net share direction 2,436 net-buy shares Net buy shares from transaction summary

Key Terms

open-market purchase, indirect ownership, Form 4, common stock

4 terms

open-market purchase financial

"transaction_action: open-market purchase of common stock"

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

indirect ownership financial

"ownership_type: indirect; shares held through CorLyst, LLC"

Form 4 regulatory

"Insider transaction reported on Form 4 for PCSA"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

common stock financial

"security_title: Common Stock for all reported entries"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/01/2026 - 04:21 PM Accepted by SEC EDGAR 07/01/2026 - 04:20 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Guy Wendy

(Last) (First) (Middle)

C/O PROCESSA PHARMACEUTICALS, INC.

601 21ST STREET SUITE 300

(Street)

VERO BEACH FLORIDA 32960

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Processa Pharmaceuticals, Inc. [ PCSA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Administrative Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/30/2026		P		2,436	A	$1.93	14,394	D
Common Stock								333	I	By CorLyst, LLC

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Wendy Guy by John J. Wolfel, as Attorney-in-Fact	07/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did PCSA executive Guy Wendy report on this Form 4?

Guy Wendy reported buying 2,436 shares of Processa Pharmaceuticals common stock. The transaction was an open-market purchase at $1.93 per share, increasing her direct ownership position as Chief Administrative Officer of the company.

How many PCSA shares does Guy Wendy own after the reported purchase?

After the transaction, Guy Wendy directly owns 14,394 Processa Pharmaceuticals shares. She also has indirect ownership of 333 additional shares held through CorLyst, LLC, as disclosed in the Form 4 insider reporting data.

At what price did Guy Wendy buy Processa Pharmaceuticals (PCSA) shares?

She purchased the shares at $1.93 per share in an open-market transaction. This price applies to the 2,436 common shares acquired and is explicitly stated as the transaction price per share in the Form 4 filing data.

What indirect PCSA holdings does Guy Wendy report through CorLyst, LLC?

The Form 4 shows 333 Processa Pharmaceuticals common shares held indirectly by CorLyst, LLC. These shares are reported as indirect ownership, separate from her directly held 14,394 shares following the open-market purchase transaction.

Does the Form 4 for PCSA show any insider sales by Guy Wendy?

No insider sales are reported for this period. The transaction summary lists one open-market purchase of 2,436 shares and no sales, resulting in a net-buy position for Guy Wendy in this filing.